Thomas Zilli

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 18

Top Topics

Benign Prostatic Hyperplasia

Radical Prostatectomy

Prostate Cancer

Top Venues

Translational andrology and urology

Prostate cancer and prostatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Francesco Mosè Castronovo, Thomas Zilli, Antonio Angrisani, Davide Giovanni Bosetti
Stereotactic ablative radiotherapy: a game-changer in primary renal cancer therapy. Translational andrology and urology 13 (7) (2024)
Matthias Guckenberger, Charlotte Billiet, Daniel Schnell, Ciro Franzese, Mateusz Jacek Spałek, Susanne Rogers, Jean-Jacques Stelmes, Daniel Matthias Aebersold, Hossein Hemmatazad, Frank Zimmermann, Jörg Zimmer, Thomas Zilli, Alessio Bruni, Brigitta Gertrud Baumert, Franziska Nägler, Philipp Gut, Robert Förster, Indira Madani
Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial. Cancer (2024)
Francesco Mosè Castronovo, Thomas Zilli, Antonio Angrisani, Davide Giovanni Bosetti
Stereotactic ablative radiotherapy: a game-changer in primary renal cancer therapy. Translational andrology and urology 13 (7) (2024)
Jennifer Le Guevelou, Francesco Cuccia, Ronan Flippot, Giuseppe Ferrera, Mario Terlizzi, Thomas Zilli, Renaud De Crevoisier, Jean-Michel Hannoun-Levi, Stephane Supiot, Paul Sargos, David Pasquier
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases (2024)
Matthias Guckenberger, Charlotte Billiet, Daniel Schnell, Ciro Franzese, Mateusz Jacek Spałek, Susanne Rogers, Jean-Jacques Stelmes, Daniel Matthias Aebersold, Hossein Hemmatazad, Frank Zimmermann, Jörg Zimmer, Thomas Zilli, Alessio Bruni, Brigitta Gertrud Baumert, Franziska Nägler, Philipp Gut, Robert Förster, Indira Madani
Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial. Cancer 130 (15) (2024)
Christina Schröder, Hongjian Tang, Paul Windisch, Daniel Rudolf Zwahlen, André Buchali, Erwin Vu, Tilman Bostel, Tanja Sprave, Thomas Zilli, Vedang Murthy, Robert Foerster
Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review. Cancers 14 (3) (2022)
Vérane Achard, Thomas Zilli
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape. Prostate cancer and prostatic diseases (2022)
Pauline Coralie Guillemin, David Sinden, Yacine M'Rad, Michael Schwenke, Jennifer Le Guevelou, Johannes W E Uiterwijk, Orane Lorton, Max Scheffler, Pierre-Alexandre Poletti, Juergen Jenne, Thomas Zilli, Rares Salomir
A Novel Concept of Transperineal Focused Ultrasound Transducer for Prostate Cancer Local Deep Hyperthermia Treatments. Cancers 15 (1) (2022)
Pauline Coralie Guillemin, David Sinden, Yacine M'Rad, Michael Schwenke, Jennifer Le Guevelou, Johannes W E Uiterwijk, Orane Lorton, Max Scheffler, Pierre-Alexandre Poletti, Juergen Jenne, Thomas Zilli, Rares Salomir
A Novel Concept of Transperineal Focused Ultrasound Transducer for Prostate Cancer Local Deep Hyperthermia Treatments. Cancers 15 (1) (2022)
Pauline Coralie Guillemin, David Sinden, Yacine M'Rad, Michael Schwenke, Jennifer Le Guevelou, Johannes W E Uiterwijk, Orane Lorton, Max Scheffler, Pierre-Alexandre Poletti, Juergen Jenne, Thomas Zilli, Rares Salomir
A Novel Concept of Transperineal Focused Ultrasound Transducer for Prostate Cancer Local Deep Hyperthermia Treatments. Cancers 15 (1) (2022)
Robert Foerster, Daniel Rudolf Zwahlen, Andre Buchali, Hongjian Tang, Christina Schroeder, Paul Windisch, Erwin Vu, Sati Akbaba, Tilman Bostel, Tanja Sprave, Constantinos Zamboglou, Thomas Zilli, Jean-Jacques Stelmes, Tejshri Telkhade, Vedang Murthy
Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. Cancers 13 (4) (2021)
Maria Antonia Gómez-Aparicio, Jeannette Valero, Begoña Caballero, Rafael García, Ovidio Hernando-Requejo, Angel Montero, Alfonso Gómez-Iturriaga, Thomas Zilli, Piet Ost, Fernando López-Campos, Felipe Couñago
Extreme Hypofractionation with SBRT in Localized Prostate Cancer. Current oncology (Toronto, Ont.) 28 (4) (2021)
Anna Patrikidou, Thomas Zilli, Giulia Baciarello, Safae Terisse, Zineb Hamilou, Karim Fizazi
Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments? Therapeutic advances in medical oncology 13 (2021)
Francesca Caparrotti, Idriss Troussier, Abdirahman Ali, Thomas Zilli
Localized Non-melanoma Skin Cancer: Risk Factors of Post-surgical Relapse and Role of Postoperative Radiotherapy. Current treatment options in oncology 21 (12) (2020)
Thomas Zilli, Sandra Jorcano, Samuel Bral, Carmen Rubio, Anna M E Bruynzeel, Angelo Oliveira, Ufuk Abacioglu, Heikki Minn, Zvi Symon, Raymond Miralbell
Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results. Cancer medicine 9 (9) (2020)
Verane Achard, Giorgio Lamanna, Antoine Denis, Thomas De Perrot, Ismini Charis Mainta, Osman Ratib, Christophe Iselin, Raymond Miralbell, Valentina Garibotto, Thomas Zilli
Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI. Medical oncology (Northwood, London, England) 36 (8) (2019)
Vérane Achard, Sandra Jorcano, Michel Rouzaud, Lluís Escudé, Raymond Miralbell, Thomas Zilli
Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter? Journal of cancer research and clinical oncology 145 (6) (2019)
Thomas Zilli, Marta Scorsetti, Daniel Zwahlen, Ciro Franzese, Robert Förster, Niccolò Giaj-Levra, Nikolaos Koutsouvelis, Aurelie Bertaut, Michel Zimmermann, Giuseppe Roberto D'Agostino, Filippo Alongi, Matthias Guckenberger, Raymond Miralbell
ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiation oncology (London, England) 13 (1) (2018)